Why the study?
Do calcium sensitizers CGP 48506 and EMD 57033 induce quantitatively similar inotropic responses in normal and failing cardiac myocytes?
Do calcium sensitizers CGP 48506 and EMD 57033 induce quantitatively similar inotropic responses in normal and failing cardiac myocytes?
Calcium sensitizers exert comparable positive inotropic effects without altering resting cell length or calcium levels in both normal and failing cardiac myocytes.
Supports calcium sensitization viability in failing myocytes; leaves open translation to clinical heart failure therapy.
Calcium sensitizers increase myocardial contractile function without affecting Ca2+ homeostasis, which might be beneficial in the treatment of patients with heart failure. However, it remains uncertain whether Ca sensitizers induce quantitatively similar inotropic responses in control and failing hearts. To compare their effects in normal versus failing hearts at the cellular level, shortening mechanics and intracellular calcium ([Ca2+]i) transient were simultaneously measured in the left ventricular myocytes isolated from normal dogs (n = 8) and dogs with rapid pacing-induced heart failure (n = 7). CGP 48506 and EMD 57033 exerted a positive inotropic effect in a dose (0.1-3 microM)-dependent manner in both normal and heart failure myocytes. The percent increase of cell shortening magnitude was comparable between the two groups. CGP 48506 and EMD 57033 did not affect the diastolic cell length and resting [Ca2+]i level. They did not affect the duration of [Ca2+]i transient dynamics. Thus Ca2+ sensitizers exerted comparable positive inotropic effects without affecting the rest cell length and rest [Ca2+]i in normal and heart failure myocytes.
No takes yet. Share an insight, caveat, or question.
Tsutsui et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: